Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Bevacizumab
Brand Name Avastin®
Payment Category Medicare Part B
Year Introduced 2004
Type of Drug Vascular endothelial growth factor-specific angiogenesis inhibitor
Manufacturer Genentech
Medical Affairs Questions (date verified) 800.821.8590
Coverage & Reimbursement Questions 866.422.2377
Billing Unit 10 mg
Medicare Payment Limit (Effective January 1, 2021) $75.16

FDA-Approved Indication(s)

  • Indicated for 1) Metastatic colorectal cancer, with a) intravenous 5-fluorouracil_based chemotherapy for first- or second-line treatment, or b) fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line Avastin containing regimen; 2) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease; 3) Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy; 4) Metastatic renal cell carcinoma with interferon alfa; 5) Cervical cancer, in combination with paclitaxel and cisplatin or topotecan in persistent, recurrent, or metastatic disease, 6) Epithelial ovarian, fallopian tube, or primary peritoneal cancer, a) in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for Stage III or IV disease following initial surgical resection, b) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for platinum resistant disease who have received no more than 2 prior chemotherapy regimens, or c) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum sensitive recurrent disease; and 7) Hepatocellular carcinoma (HCC), in combination with atezolizumab, for the treatment of patientswith unresectable or metastatic HCC who have not received prior systemic therapy. (8/25/20)

Approved Indication(s) with Orphan Drug Status 1)Treatment of renal cell carcinoma. 2) Therapeutic treatment of patients with ovarian cancer. 3) Treatment of malignant glioma. 4) Treatment of primary peritoneal carcinoma. 5)Treatment of fallopian tube carcinoma
ICD-10 Code(s) for Labeled Indication(s) Colorectal cancers [C18.x, C19, C20,or C21.x, dependent on location]; Malignant neoplasm of bronchus and lung [C34.xx]; Malignant neoplasm of brain [C71.x]; Malignant neoplasm of kidney [C64.x] or renal pelvis [C65.x]; Malignant neoplasm of cervix uteri [C53.x]; Malignant neoplasm of ovary [C56.x] or fallopian tube [C57.x]; Hepatocellular carcinoma [C22.0]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949